GBP2 Recombinant Monoclonal Antibody

Guanylate-binding protein 2 (GBP2) serves as a critical effector in interferon-mediated immune responses, functioning as a GTPase that plays essential roles in host defense against intracellular pathogens and in inflammatory signaling pathways. As an interferon-induced protein, GBP2 has emerged as an important target in studies of innate immunity, antimicrobial defense mechanisms, and increasingly in cancer immunology research where its expression patterns may influence tumor microenvironment dynamics.

This recombinant monoclonal antibody against human GBP2 offers researchers the reproducibility advantages inherent to sequence-defined antibody production. Unlike traditional hybridoma-derived antibodies, recombinant technology ensures consistent performance across lots, providing reliable results whether you're establishing baseline protocols or conducting long-term studies requiring comparable data across experiments.

The antibody has been validated across multiple detection platforms, offering flexibility for diverse experimental workflows. Western blot analysis in U-251MG glioblastoma cell lysates demonstrates specific detection of GBP2 at the expected 67 kDa molecular weight, confirming accurate target recognition. Immunofluorescence studies in HeLa cells reveal clear cytoplasmic localization patterns consistent with GBP2's known subcellular distribution, while flow cytometry validation in A431 epidermoid carcinoma cells shows distinct positive signal separation from isotype controls, enabling quantitative analysis of GBP2 expression at the single-cell level.

The human IgG1 isotype format and affinity-purified preparation support clean detection with minimal background when paired with appropriate anti-human secondary reagents. This GBP2 antibody serves researchers investigating interferon signaling, innate immune responses, infectious disease mechanisms, and the growing field of GBP family proteins in cancer biology and inflammatory conditions.